Alzheimer’s disease and the cystatin C gene polymorphism: an association study

Cystatin C is an amyloidogenic protein that colocalizes with beta-amyloid (Abeta) within arteriolar walls in Alzheimer disease (AD) brains. Recently, a coding polymorphism in the cystatin C gene (CST3) has been claimed to confer risk for the development of late-onset AD. In the present work we have tested the frequencies of CST3-A and CST3-G alleles and used chi-square and logistic regression analyses to assess the association among the CST3 polymorphism, apolipoprotein E4 (APOE4), and AD in a series of 159 AD patients and 155 controls. The CST3-A allele was seen to be an accumulation risk factor for early-onset AD. Furthermore, a synergistic association among the CST3-A allele, APOE4 and AD was found in AD patients whose ages were between 60 and 74 years.

[1]  B T Hyman,et al.  Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. , 2000, Archives of neurology.

[2]  Bonnie F. Sloane,et al.  Intracellular accumulation of the amyloidogenic L68Q variant of human cystatin C in NIH/3T3 cells. , 1998, Molecular pathology : MP.

[3]  A. Roses.  Alzheimer diseases: a model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases. , 1998, American journal of medical genetics.

[4]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[5]  H. Vinters,et al.  Microvascular degeneration in hereditary cystatin C amyloid angiopathy of the brain , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[6]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[7]  H. Wiśniewski,et al.  Cellular processing of the amyloidogenic cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. , 1999, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[8]  M. Manfredi,et al.  The prevalence of apoE-ε4 in Alzheimer’s disease is age dependent , 1998 .

[9]  K. Welsh-Bohmer,et al.  APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease , 1998, Nature Genetics.

[10]  C. López-Otín,et al.  Stroke in Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine proteases , 1989, The Journal of experimental medicine.

[11]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[12]  D. Graham,et al.  The Apolipoprotein E ∈2 Allele and the Pathological Features in Cerebral Amyloid Angiopathy-related Hemorrhage , 1999 .

[13]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[14]  H. Vinters,et al.  Immunoreactive A4 and gamma-trace peptide colocalization in amyloidotic arteriolar lesions in brains of patients with Alzheimer's disease. , 1990, The American journal of pathology.

[15]  M. Gold,et al.  A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease , 2000, Neurology.